Pharmacological Characterization of a Novel Centrally Permeable P2X7 Receptor Antagonist: JNJ-47965567

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2013 Jul 30

PMID 23889535

Citations 90

Authors

Anindya Bhattacharya

Qi Wang

Hong Ao

James R Shoblock

Brian Lord

Leah Aluisio

Ian Fraser

Diane Nepomuceno

Robert A Neff

Natalie Welty

Timothy W Lovenberg

Pascal Bonaventure

Alan D Wickenden

Michael A Letavic

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: An increasing body of evidence suggests that the purinergic receptor P2X, ligand-gated ion channel, 7 (P2X7) in the CNS may play a key role in neuropsychiatry, neurodegeneration and chronic pain. In this study, we characterized JNJ-47965567, a centrally permeable, high-affinity, selective P2X7 antagonist.

Experimental Approach: We have used a combination of in vitro assays (calcium flux, radioligand binding, electrophysiology, IL-1β release) in both recombinant and native systems. Target engagement of JNJ-47965567 was demonstrated by ex vivo receptor binding autoradiography and in vivo blockade of Bz-ATP induced IL-1β release in the rat brain. Finally, the efficacy of JNJ-47965567 was tested in standard models of depression, mania and neuropathic pain.

Key Results: JNJ-47965567 is potent high affinity (pKi 7.9 ± 0.07), selective human P2X7 antagonist, with no significant observed speciation. In native systems, the potency of the compound to attenuate IL-1β release was 6.7 ± 0.07 (human blood), 7.5 ± 0.07 (human monocytes) and 7.1 ± 0.1 (rat microglia). JNJ-47965567 exhibited target engagement in rat brain, with a brain EC50 of 78 ± 19 ng·mL(-1) (P2X7 receptor autoradiography) and functional block of Bz-ATP induced IL-1β release. JNJ-47965567 (30 mg·kg(-1) ) attenuated amphetamine-induced hyperactivity and exhibited modest, yet significant efficacy in the rat model of neuropathic pain. No efficacy was observed in forced swim test.

Conclusion And Implications: JNJ-47965567 is centrally permeable, high affinity P2X7 antagonist that can be used to probe the role of central P2X7 in rodent models of CNS pathophysiology.

Citing Articles

Pharmacology of P2X Receptors and Their Possible Therapeutic Potential in Obesity and Diabetes.

Cabral-Garcia G, Cruz-Munoz J, Valdez-Morales E, Barajas-Espinosa A, Linan-Rico A, Guerrero-Alba R Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39458933 PMC: 11509955. DOI: 10.3390/ph17101291.

Unlocking the therapeutic potential of P2X7 receptor: a comprehensive review of its role in neurodegenerative disorders.

Liu X, Li Y, Huang L, Kuang Y, Wu X, Ma X Front Pharmacol. 2024; 15:1450704.

PMID: 39139642 PMC: 11319138. DOI: 10.3389/fphar.2024.1450704.

The effect of P2X7 antagonism on subcortical spread of optogenetically-triggered cortical spreading depression and neuroinflammation.

Uzay B, Donmez-Demir B, Ozcan S, Kocak E, Yemisci M, Gursoy Ozdemir Y J Headache Pain. 2024; 25(1):120.

PMID: 39044141 PMC: 11267761. DOI: 10.1186/s10194-024-01807-1.

A Hybrid Approach Combining Shape-Based and Docking Methods to Identify Novel Potential P2X7 Antagonists from Natural Product Databases.

da Silva Ferreira N, Viviani L, Lima L, Amaral A, Romano J, Fortunato A Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794162 PMC: 11123696. DOI: 10.3390/ph17050592.

Ionotropic purinergic receptor 7 (P2X7) channel structure and pharmacology provides insight regarding non-nucleotide agonism.

Al-Aqtash R, Collier D Channels (Austin). 2024; 18(1):2355150.

PMID: 38762911 PMC: 11110710. DOI: 10.1080/19336950.2024.2355150.

References

Browne L, Jiang L, North R . New structure enlivens interest in P2X receptors. Trends Pharmacol Sci. 2010; 31(5):229-37. PMC: 2954318. DOI: 10.1016/j.tips.2010.02.004. View

Kim S, Chung J . An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain. 1992; 50(3):355-363. DOI: 10.1016/0304-3959(92)90041-9. View

Baxter A, Bent J, Bowers K, Braddock M, Brough S, Fagura M . Hit-to-Lead studies: the discovery of potent adamantane amide P2X7 receptor antagonists. Bioorg Med Chem Lett. 2003; 13(22):4047-50. DOI: 10.1016/j.bmcl.2003.08.034. View

Hattori M, Gouaux E . Molecular mechanism of ATP binding and ion channel activation in P2X receptors. Nature. 2012; 485(7397):207-12. PMC: 3391165. DOI: 10.1038/nature11010. View

Khakh B, North R . Neuromodulation by extracellular ATP and P2X receptors in the CNS. Neuron. 2012; 76(1):51-69. PMC: 4064466. DOI: 10.1016/j.neuron.2012.09.024. View

Burnstock G, Krugel U, Abbracchio M, Illes P . Purinergic signalling: from normal behaviour to pathological brain function. Prog Neurobiol. 2011; 95(2):229-74. DOI: 10.1016/j.pneurobio.2011.08.006. View

Kilkenny C, Browne W, Cuthill I, Emerson M, Altman D . Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol. 2010; 160(7):1577-9. PMC: 2936830. DOI: 10.1111/j.1476-5381.2010.00872.x. View

Soderlund J, Olsson S, Samuelsson M, Walther-Jallow L, Johansson C, Erhardt S . Elevation of cerebrospinal fluid interleukin-1ß in bipolar disorder. J Psychiatry Neurosci. 2010; 36(2):114-8. PMC: 3044194. DOI: 10.1503/jpn.100080. View

Basso A, Bratcher N, Harris R, Jarvis M, Decker M, Rueter L . Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: relevance for neuropsychiatric disorders. Behav Brain Res. 2008; 198(1):83-90. DOI: 10.1016/j.bbr.2008.10.018. View

10.

Sperlagh B, Vizi E, Wirkner K, Illes P . P2X7 receptors in the nervous system. Prog Neurobiol. 2006; 78(6):327-46. DOI: 10.1016/j.pneurobio.2006.03.007. View

11.

Abbracchio M, Burnstock G, Verkhratsky A, Zimmermann H . Purinergic signalling in the nervous system: an overview. Trends Neurosci. 2008; 32(1):19-29. DOI: 10.1016/j.tins.2008.10.001. View

12.

Backlund L, Nikamo P, Hukic D, Romer Ek I, Traskman-Bendz L, Landen M . Cognitive manic symptoms associated with the P2RX7 gene in bipolar disorder. Bipolar Disord. 2011; 13(5-6):500-8. DOI: 10.1111/j.1399-5618.2011.00952.x. View

13.

North R, Jarvis M . P2X receptors as drug targets. Mol Pharmacol. 2012; 83(4):759-69. PMC: 3608433. DOI: 10.1124/mol.112.083758. View

14.

Shiratori M, Tozaki-Saitoh H, Yoshitake M, Tsuda M, Inoue K . P2X7 receptor activation induces CXCL2 production in microglia through NFAT and PKC/MAPK pathways. J Neurochem. 2010; 114(3):810-9. DOI: 10.1111/j.1471-4159.2010.06809.x. View

15.

Goshen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur T . Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry. 2007; 13(7):717-28. DOI: 10.1038/sj.mp.4002055. View

16.

Hejjas K, Szekely A, Domotor E, Halmai Z, Balogh G, Schilling B . Association between depression and the Gln460Arg polymorphism of P2RX7 gene: a dimensional approach. Am J Med Genet B Neuropsychiatr Genet. 2008; 150B(2):295-9. DOI: 10.1002/ajmg.b.30799. View

17.

Able S, Fish R, Bye H, Booth L, Logan Y, Nathaniel C . Receptor localization, native tissue binding and ex vivo occupancy for centrally penetrant P2X7 antagonists in the rat. Br J Pharmacol. 2010; 162(2):405-14. PMC: 3031061. DOI: 10.1111/j.1476-5381.2010.01025.x. View

18.

Surprenant A, North R . Signaling at purinergic P2X receptors. Annu Rev Physiol. 2008; 71:333-59. DOI: 10.1146/annurev.physiol.70.113006.100630. View

19.

Bhattacharya A, Neff R, Wickenden A . The physiology, pharmacology and future of P2X7 as an analgesic drug target: hype or promise?. Curr Pharm Biotechnol. 2011; 12(10):1698-706. DOI: 10.2174/138920111798357429. View

20.

Koo J, Duman R . Interleukin-1 receptor null mutant mice show decreased anxiety-like behavior and enhanced fear memory. Neurosci Lett. 2009; 456(1):39-43. PMC: 3678367. DOI: 10.1016/j.neulet.2009.03.068. View